Amgen (NASDAQ:AMGN) reported Q2 non-GAAP diluted earnings of $5.00, up from $4.65 a year earlier.
Analysts surveyed by Capital IQ expected $4.49.
Revenue for the quarter ended June 30 was $6.99 billion, up from $6.59 billion a year earlier.
Analysts surveyed by Capital IQ expected $6.68 billion.
The company said it now expects fiscal 2023 non-GAAP diluted earnings of $17.80 to $18.80 per share, up from its prior guidance of $17.60 to $18.70. Analysts surveyed by Capital IQ are expecting $17.70.
Revenue for the year is now projected to be in the range of $26.60 billion to $27.40 billion, the company said. That compares with its prior guidance of $26.20 billion to $27.30 billion. Analysts surveyed by Capital IQ are looking for $27.32 billion.
The company also said it expects share buybacks not to exceed $500 million.